ABCL ABCL
Company Profile ↓Company Overview
ABCL (ABCL) is a publicly traded company listed on with a market capitalization of $1.78B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $75.13M (+160.6% YoY); net profit $-146.41M.
- Trailing 12 Months Year-on-year growth — revenue +160.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -46.3%, profit CAGR -64.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -46.31% |
| 1 Year: | 160.56% |
Compounded Profit Growth
| 5 Years: | -64.12% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +36.41% |
| 6 Months: | +68.18% |
| 3 Months: | +27.04% |
| 1 Month: | -23.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -46.3% CAGR over 5 years.
- Earnings shrank at -64.1% CAGR over 5 years.
- Trading 27.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66M | 11.23M | 9.36M | 202.74M | 27.64M | 5.51M | 316.58M | 45.92M | 101.38M | 12.19M | 10.06M | 6.60M | 9.95M | 7.32M | 6.51M | - | 4.24M | 17.08M | 8.96M | 44.85M | 8.31M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.74M | 62.98M | 82.50M | 70.12M | 61.49M |
| Operating Income | -2.12M | -854.00K | -1.77M | 158.07M | -7.03M | -28.10M | 224.95M | -8.40M | 37.73M | -64.87M | -51.39M | -54.89M | -54.89M | -93.45M | -93.66M | - | -58.51M | -45.89M | -73.55M | -25.27M | -53.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51.90M | -38.83M | -66.31M | -17.35M | -44.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -52.98M | -36.34M | -68.77M | -19.50M | -49.54M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.36M | -1.62M | -11.65M | -10.55M | -6.37M |
| Net Income | -2.09M | 6.70M | -2.69M | 117.22M | -2.32M | -21.38M | 168.57M | -6.79M | 26.62M | -40.11M | -30.53M | -28.61M | -40.61M | -36.93M | -51.11M | - | -45.62M | -34.73M | -57.12M | -8.95M | -43.16M |
| Diluted EPS | -0.01 | 0.03 | -0.02 | 0.37 | -0.01 | -0.08 | 0.54 | -0.02 | 0.08 | -0.14 | -0.11 | -0.10 | -0.14 | -0.13 | -0.17 | - | -0.15 | -0.12 | -0.19 | - | -0.14 |
| R&D Expense | 4.12M | 9.14M | 7.50M | 12.35M | 15.05M | 17.45M | 26.37M | 26.68M | 26.58M | 52.65M | 36.47M | 37.92M | 39.29M | 40.93M | 40.97M | - | 42.50M | 39.21M | 55.03M | - | 46.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.61M | 233.16M | - | 485.42M | 38.02M | 28.83M | 75.13M |
| Cost of Revenue | - | - | 45.52M | 66.44M | 0 | 0 | - |
| Gross Profit | - | - | 329.69M | 418.99M | 38.02M | 28.83M | - |
| Operating Expenses | - | - | - | 191.92M | 261.08M | 329.98M | 278.34M |
| Operating Income | -4.12M | 156.03M | - | 227.06M | -223.05M | -301.15M | -203.21M |
| EBITDA | - | - | - | 260.17M | -192.16M | -204.15M | -174.39M |
| Interest Expense | - | - | 5.22M | 4.04M | - | - | - |
| Pretax Income | - | - | - | 239.10M | -174.03M | -200.40M | -177.59M |
| Tax Provision | - | - | - | 80.58M | -27.63M | -37.54M | -31.18M |
| Net Income | -2.21M | 118.92M | - | 158.52M | -146.40M | -162.86M | -146.41M |
| Diluted EPS | -0.01 | 0.45 | - | 0.50 | -0.51 | -0.55 | -0.49 |
| R&D Expense | 10.11M | 29.39M | 62.06M | 107.88M | 175.66M | 167.26M | 186.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.01B | - | 1.54B | 1.49B | 1.36B | 1.36B |
| Current Assets | - | - | - | - | 1.03B | 871.99M | 751.37M | 728.23M |
| Cash & Equivalents | - | - | 594.12M | - | 386.54M | 133.32M | 156.32M | 128.51M |
| Inventory | - | - | - | - | 1.53M | 1.11M | 0 | 6.34M |
| Receivables | - | - | - | - | 38.59M | 30.59M | 33.62M | 58.29M |
| Total Liabilities | - | - | 175.03M | - | 307.63M | 335.78M | 304.47M | 390.05M |
| Current Liabilities | - | - | 103.49M | - | 118.32M | 119.01M | 76.61M | 64.31M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 82.26M | 77.38M | 65.36M | 143.22M |
| Total Equity | 11.61M | 10.25M | 830.51M | - | 1.23B | 1.15B | 1.06B | 966.90M |
| Shares Outstanding | - | - | - | - | 286.85M | 290.82M | 295.76M | 300.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.69M | 22.69M | - | 277.36M | -43.88M | -108.56M | -131.29M |
| Investing Cash Flow | -5.78M | -119.78M | - | -352.62M | -221.11M | 121.41M | 87.75M |
| Financing Cash Flow | 195.00K | 683.65M | - | -1.63M | 10.36M | 12.77M | 14.08M |
| Capital Expenditure | -4.00M | -9.67M | - | -72.66M | -76.95M | -78.40M | -42.77M |
| Free Cash Flow | -1.30M | 13.02M | - | 204.70M | -120.82M | -186.95M | -174.07M |
| Net Change in Cash | - | - | - | -76.89M | -254.63M | 25.62M | -29.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 86.3% | 100.0% | 100.0% | - |
| Operating Margin % | -35.5% | 66.9% | - | 46.8% | -586.6% | -1,044.4% | -270.5% |
| Net Margin % | -19.0% | 51.0% | - | 32.7% | -385.0% | -564.8% | -194.9% |
| ROE % | -21.6% | 14.3% | - | 12.9% | -12.7% | -15.4% | -15.1% |
| ROCE % | - | 17.3% | - | 16.0% | -16.3% | -23.5% | -15.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABCL
AbCellera Biologics Q2 Earnings Call Highlights
AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. Presi…
AbCellera Reports Q2 2026 Business Results
VANCOUVER, British Columbia, August 05, 2026--AbCellera Reports Q2 2026 Business Results
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?
Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and other conditions. Under the agreement, Vertex will fund the resear…
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
VANCOUVER, British Columbia, July 29, 2026--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial …
ABCL — Frequently Asked Questions
What is the current share price of ABCL?
As of 2026-08-05 17:25 PDT, ABCL trades at $5.92 on NASDAQ/NYSE. Its 52-week range is $2.78 to $8.12.
What is the market capitalisation of ABCL?
ABCL has a market capitalisation of $1.78B on NASDAQ/NYSE.
What is the P/E ratio of ABCL?
ABCL trades at a trailing price-to-earnings (P/E) ratio of -12.08. Its price-to-book (P/B) ratio is 1.84.
What is the return on equity (ROE) of ABCL?
ABCL has a return on equity (ROE) of -15.14%. Its return on capital employed (ROCE) is -15.72%.
Is ABCL a good stock to buy?
This page provides a data-driven analysis of ABCL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.